EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study

Kenji Takeshita iD, Muneharu Fujisaki iD, Motohiro Shionozaki iD, Kazuhide Sato iD, Mizuki Fukuda iD, Naoko Fukushima iD, Yoshitaka Ishikawa iD, Yuta Takano iD, Fumiaki Yano iD, Ken Eto iD

Journal of Gastric Cancer · 2026 · 26 (4) · 598

DOI: 10.5230/jgc.2026.26.e46 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastric Cancer, 2026. Verfasst von Kenji Takeshita und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan. ken.take0817@gmail.com. Hauptthemen laut MEDLINE: Stomach Neoplasms, Nivolumab, C-Reactive Protein, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The C-reactive protein-albumin-lymphocyte (CALLY) index is a novel immuno-nutritional marker in various cancers. We investigated its prognostic value in patients with unresectable or recurrent gastric cancer who were treated with nivolumab monotherapy. MATERIALS AND METHODS: This multicenter retrospective study included 126 patients treated with third- or later-line nivolumab monotherapy. The CALLY index was calculated as (Albumin × Lymphocyte Count)/(C-Reactive Protein × 10⁴) and dichotomized at 1.08. The operating characteristics of this cutoff were evaluated using receiver operating characteristic analysis for 1-year overall survival (OS). OS and progression-free survival (PFS) were evaluated. RESULTS: The CALLY-low group exhibited a significantly shorter median OS (164 vs. 377 days; P=0.004) and median PFS (56 vs. 104 days; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsNivolumabC-Reactive ProteinNeoplasm Recurrence, LocalAntineoplastic Agents, ImmunologicalHumansRetrospective StudiesFemaleMaleAgedPrognosisMiddle AgedLymphocyte CountBiomarkers, TumorAdult

Stichwörter der Autor:innen

BiomarkersImmune checkpoint inhibitorsNivolumabPrognosisStomach neoplasms

Substanzen

NivolumabC-Reactive ProteinAntineoplastic Agents, ImmunologicalBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan. ken.take0817@gmail.com.
  • Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Surgery, The Jikei University Katsushika Medical Center, Tokyo, Japan.
  • Department of Surgery, The Jikei University Kashiwa Hospital, Kashiwa, Japan.

ORCID-Profile: Kenji Takeshita, Muneharu Fujisaki, Motohiro Shionozaki, Kazuhide Sato, Mizuki Fukuda, Naoko Fukushima, Yoshitaka Ishikawa, Yuta Takano, Fumiaki Yano, Ken Eto

Zitieren

APA

Takeshita, K., Fujisaki, M., Shionozaki, M., Sato, K., Fukuda, M., Fukushima, N., Ishikawa, Y., Takano, Y., Yano, F., & Eto, K. (2026). The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study. Journal of Gastric Cancer, 26(4), 598. https://doi.org/10.5230/jgc.2026.26.e46

Vancouver

Takeshita K, Fujisaki M, Shionozaki M, Sato K, Fukuda M, Fukushima N, et al. The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study. Journal of Gastric Cancer. 2026;26(4):598. doi:10.5230/jgc.2026.26.e46

BibTeX
@article{Takeshita2026,
  author = {Takeshita, Kenji and Fujisaki, Muneharu and Shionozaki, Motohiro and Sato, Kazuhide and Fukuda, Mizuki and Fukushima, Naoko and Ishikawa, Yoshitaka and Takano, Yuta and Yano, Fumiaki and Eto, Ken},
  title = {The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study},
  journal = {Journal of Gastric Cancer},
  year = {2026},
  volume = {26},
  number = {4},
  pages = {598},
  doi = {10.5230/jgc.2026.26.e46}
}
Kostenlos starten →